Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Sci Rep. 2019 Dec 24;9(1):19743. doi: 10.1038/s41598-019-56119-1.
This is a retrospective study examining the efficacy and safety of Gamma Knife radiosurgery (GKS) in treating patients with cerebral cavernous malformations (CCMs). Between 1993 and 2018, 261 patients with 331 symptomatic CCMs were treated by GKS. The median age was 39.9 years and females were predominant (54%). The median volume of CCMs was 3.1 mL. The median margin dose was 11.9 Gy treat to a median isodose level of 59%. Median clinical and imaging follow-up times were 69 and 61 months, respectively. After the initial hemorrhage that led to CCM diagnosis, 136 hemorrhages occurred in the period prior to GKS (annual incidence = 23.6%). After GKS, 15 symptomatic hemorrhages occurred within the first 2 years of follow-up (annual incidence = 3.22%), and 37 symptomatic hemorrhages occurred after the first 2 years of follow-up (annual incidence = 3.16%). Symptomatic radiation-induced complication was encountered in 8 patients (3.1%). Mortality related to GKS occurred in 1 patient (0.4%). In conclusion, GKS decreased the risk of hemorrhage in CCM patients presenting with symptomatic hemorrhage. GKS is a viable alternative treatment option for patients with surgically-inaccessible CCMs or significant medical comorbidities.
这是一项回顾性研究,旨在探讨伽玛刀放射外科(GKS)治疗脑动静脉畸形(CCM)患者的疗效和安全性。1993 年至 2018 年间,对 261 例 331 个有症状的 CCM 患者进行了 GKS 治疗。患者的中位年龄为 39.9 岁,女性居多(54%)。CCM 的中位体积为 3.1ml。中位边缘剂量为 11.9Gy,治疗至 59%等剂量线。中位临床和影像学随访时间分别为 69 个月和 61 个月。在导致 CCM 诊断的初始出血后,在 GKS 治疗前期间发生了 136 次出血(年发生率为 23.6%)。GKS 治疗后,在最初 2 年的随访期间发生了 15 次症状性出血(年发生率为 3.22%),在最初 2 年的随访后发生了 37 次症状性出血(年发生率为 3.16%)。8 例患者(3.1%)发生了症状性放射性并发症。1 例患者(0.4%)与 GKS 相关死亡。总之,GKS 降低了有症状出血的 CCM 患者出血的风险。GKS 是一种可行的治疗选择,适用于手术无法到达的 CCM 或存在严重合并症的患者。